Jack F. Shern

National Institutes of Health — United States

Medicine · Health Sciences

41h-index9.5kcitations510works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(171), CAR-T cell therapy research(74), Neuroblastoma Research and Treatments(68), Protein Degradation and Inhibitors(68), Cancer-related molecular mechanisms research(55)

Publications510 total

The prostate is a common site of disease in patients with MEN2B and medullary thyroid carcinoma
Endocrine Related Cancer·2025Open Access
Activity of Direct KRAS(G12C) Inhibitors in Preclinical Models of Pediatric Cancer
Molecular Cancer Therapeutics·2025· 1 citedOpen Access
Supplementary Data File S5 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
2025Open Access
Figure S2 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
2025Open Access
Supplementary Figure S3 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
2025Open Access
Figure 5 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
2025Open Access
Supplementary Figure S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
2025Open Access
Figure 2 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
2025Open Access
Supplementary Data File S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
2025Open Access
Supplementary Data File S9 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
2025Open Access
Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
2025Open Access
Supplementary Figure S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
2025Open Access
Supplementary Data File S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
2025Open Access
Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
2025Open Access
Supplementary_Methods1 from Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group
2025Open Access
Supplemental Figure S4 from Inhibition of NAD<sup>+</sup>-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
2025Open Access
Supplementary Data File S8 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
2025Open Access
Supplemental Figure S6 from Inhibition of NAD<sup>+</sup>-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
2025Open Access
Supplementary Figure S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
2025Open Access
Supplementary Figure S2 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
2025Open Access
page 1 of 26Next →

Frequent Co-authors

Javed Khan(22), Young Song(13), Marielle E. Yohe(12), Jun S. Wei(10), Sivasish Sindiri(10), Douglas S. Hawkins(10), Terry J. Fry(9), Haiyan Lei(9), Berkley E. Gryder(8), Xiyuan Zhang(8), Nirali N. Shah(7), Stephen X. Skapek(6), Xinyu Wen(6), Maryalice Stetler‐Stevenson(5), Constance M. Yuan(5), Bonnie Yates(5), Haneen Shalabi(5), Haiying Qin(5), Rajesh Patidar(5), Hsien-Chao Chou(5)